CORT Corcept Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CORT

Price (delayed)

$90.21

Market cap

$9.68B

P/E Ratio

196.11

Dividend/share

N/A

EPS

$0.46

Enterprise value

$9.59B

?
Relative Growth: Rel. Growth: 44
Relative Strength: Rel. Strength: 92
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 43

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® ...

Highlights
The gross profit is up by 12% year-on-year
The revenue rose by 12% year-on-year
The P/E is 195% more than the last 4 quarters average of 66.4
CORT's net income has shrunk by 65% YoY and by 52% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.corcept.com
Peers: JNJ BMY PFE LLY

Key stats

What are the main financial stats of CORT

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
1.96%
1 week
6.44%
1 month
26.7%
1 year
26.45%
YTD
159.22%
QTD
3.75%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$769.1M
Gross profit
$755.64M
Operating income
-$8.22M
Net income
$46.67M
Gross margin
98.3%
Net margin
6.1%
The operating margin has plunged by 119% from the previous quarter and by 107% YoY
Corcept Therapeutics's operating income has plunged by 118% from the previous quarter and by 107% YoY
Corcept Therapeutics's net margin has shrunk by 68% YoY and by 53% QoQ
CORT's net income has shrunk by 65% YoY and by 52% QoQ

Price vs fundamentals

How does CORT's price correlate with its fundamentals

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
CORT P/E details
P/E
196.11
P/B
15.04
P/S
12.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.46
The P/E is 195% more than the last 4 quarters average of 66.4
The EPS has dropped by 64% year-on-year and by 52% since the previous quarter
The stock's price to book (P/B) is 109% more than its 5-year quarterly average of 7.2 and 57% more than its last 4 quarters average of 9.6
The company's equity fell by 7% YoY
CORT's P/S is 68% above its 5-year quarterly average of 7.3 and 51% above its last 4 quarters average of 8.1
The revenue rose by 12% year-on-year

Efficiency

How efficient is Corcept Therapeutics business performance
CORT's ROIC has dropped by 121% since the previous quarter and by 108% year-on-year
The return on sales has dropped by 121% since the previous quarter and by 108% year-on-year
CORT's return on assets has dropped by 66% year-on-year and by 52% since the previous quarter
The return on equity has dropped by 64% year-on-year and by 52% since the previous quarter

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The total liabilities has grown by 8% YoY but it has contracted by 6% from the previous quarter
The company's current ratio fell by 7% YoY and by 2.1% QoQ
Corcept Therapeutics's debt is 98% lower than its equity
CORT's debt to equity has soared by 100% QoQ and by 100% YoY
Corcept Therapeutics's debt has surged by 58% QoQ and by 41% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.